Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.59 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.51 |
| ▸ | BTK | Q06187 | 2/20 | 0.51 |
| ▸ | AR | P10275 | 2/20 | 0.50 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.47 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ITK | Q08881 | 1/20 | 0.47 |
| ▸ | PLK4 | O00444 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31447942 | 0.93 | CRBN (0.62) | CRBNBTKARDDB1IKZF3 | |
| SCHEMBL31447960 | 0.88 | CRBN (0.57) | CRBNALKBTKARDDB1 | |
| SCHEMBL26702869 | 0.85 | CRBN (0.71) | CRBNALKBTKARDDB1 | |
| SCHEMBL30182975 | 0.85 | CRBN (0.68) | CRBNALKBTKARDDB1 | |
| SCHEMBL23729517 | 0.85 | CRBN (0.67) | CRBNALKBTKARDDB1 | |
| SCHEMBL27098665 | 0.84 | CRBN (0.63) | CRBNALKBTKARDDB1 | |
| SCHEMBL29260054 | 0.84 | CRBN (0.66) | CRBNALKBTKARDDB1 | |
| SCHEMBL23705474 | 0.83 | CRBN (0.62) | CRBNALKBTKARDDB1 | |
| SCHEMBL31338167 | 0.83 | CRBN (0.60) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL29058479 | 0.83 | CRBN (0.62) | CRBNALKBTKARDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250041429-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2025-02-06 | — | — | US | claimed |
| US-20250041429-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2025-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250041429-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | BTK, LYN, SYK | CRBN 324/4885ALK 1206/4885BTK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.